Cargando…
Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction
AIMS: Reactive oxygen species are reportedly involved in the mechanism underlying heart failure with preserved ejection fraction (HFpEF); however, the disease pathophysiology remains poorly understood. Xanthine oxidoreductase (XOR), the rate‐limiting enzyme of purine metabolism, plays an important r...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373896/ https://www.ncbi.nlm.nih.gov/pubmed/32432414 http://dx.doi.org/10.1002/ehf2.12734 |
_version_ | 1783561583239102464 |
---|---|
author | Watanabe, Ken Watanabe, Tetsu Otaki, Yoichiro Shishido, Tetsuro Murase, Takayo Nakamura, Takashi Kato, Shigehiko Tamura, Harutoshi Nishiyama, Satoshi Takahashi, Hiroki Arimoto, Takanori Watanabe, Masafumi |
author_facet | Watanabe, Ken Watanabe, Tetsu Otaki, Yoichiro Shishido, Tetsuro Murase, Takayo Nakamura, Takashi Kato, Shigehiko Tamura, Harutoshi Nishiyama, Satoshi Takahashi, Hiroki Arimoto, Takanori Watanabe, Masafumi |
author_sort | Watanabe, Ken |
collection | PubMed |
description | AIMS: Reactive oxygen species are reportedly involved in the mechanism underlying heart failure with preserved ejection fraction (HFpEF); however, the disease pathophysiology remains poorly understood. Xanthine oxidoreductase (XOR), the rate‐limiting enzyme of purine metabolism, plays an important role in uric acid production and generates reactive oxygen species. However, the impact of plasma XOR activity on the clinical outcomes of patients with HFpEF remains unclear. The aim of this study was to investigate whether plasma XOR activity is associated with major adverse cardiovascular events (MACEs) in patients with HFpEF. METHODS AND RESULTS: The plasma XOR activity was measured in 257 patients with HFpEF, who were then divided into three groups according to the activity levels: low XOR group (<33 pmol/h/mL, n = 45), normal XOR group (33–120 pmol/h/mL, n = 160), and high XOR group (>120 pmol/h/mL, n = 52). During the median follow‐up period of 809 days, there were 74 MACEs. Kaplan–Meier analysis revealed that the high XOR group was at the highest risk for MACEs. Multivariate analysis by Cox's proportional hazard regression approach showed that high XOR activity was significantly associated with MACEs, after adjustment for confounding factors. The patients were also divided into four groups according to the absence/presence of high XOR activity and/or hyperuricaemia. According to the multivariate Cox regression analysis, high XOR activity was associated with MACEs, regardless of the hyperuricaemia status. CONCLUSIONS: Elevated plasma XOR activity is significantly associated with adverse clinical outcomes in patients with HFpEF. |
format | Online Article Text |
id | pubmed-7373896 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73738962020-07-22 Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction Watanabe, Ken Watanabe, Tetsu Otaki, Yoichiro Shishido, Tetsuro Murase, Takayo Nakamura, Takashi Kato, Shigehiko Tamura, Harutoshi Nishiyama, Satoshi Takahashi, Hiroki Arimoto, Takanori Watanabe, Masafumi ESC Heart Fail Original Research Articles AIMS: Reactive oxygen species are reportedly involved in the mechanism underlying heart failure with preserved ejection fraction (HFpEF); however, the disease pathophysiology remains poorly understood. Xanthine oxidoreductase (XOR), the rate‐limiting enzyme of purine metabolism, plays an important role in uric acid production and generates reactive oxygen species. However, the impact of plasma XOR activity on the clinical outcomes of patients with HFpEF remains unclear. The aim of this study was to investigate whether plasma XOR activity is associated with major adverse cardiovascular events (MACEs) in patients with HFpEF. METHODS AND RESULTS: The plasma XOR activity was measured in 257 patients with HFpEF, who were then divided into three groups according to the activity levels: low XOR group (<33 pmol/h/mL, n = 45), normal XOR group (33–120 pmol/h/mL, n = 160), and high XOR group (>120 pmol/h/mL, n = 52). During the median follow‐up period of 809 days, there were 74 MACEs. Kaplan–Meier analysis revealed that the high XOR group was at the highest risk for MACEs. Multivariate analysis by Cox's proportional hazard regression approach showed that high XOR activity was significantly associated with MACEs, after adjustment for confounding factors. The patients were also divided into four groups according to the absence/presence of high XOR activity and/or hyperuricaemia. According to the multivariate Cox regression analysis, high XOR activity was associated with MACEs, regardless of the hyperuricaemia status. CONCLUSIONS: Elevated plasma XOR activity is significantly associated with adverse clinical outcomes in patients with HFpEF. John Wiley and Sons Inc. 2020-05-20 /pmc/articles/PMC7373896/ /pubmed/32432414 http://dx.doi.org/10.1002/ehf2.12734 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Articles Watanabe, Ken Watanabe, Tetsu Otaki, Yoichiro Shishido, Tetsuro Murase, Takayo Nakamura, Takashi Kato, Shigehiko Tamura, Harutoshi Nishiyama, Satoshi Takahashi, Hiroki Arimoto, Takanori Watanabe, Masafumi Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction |
title | Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction |
title_full | Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction |
title_fullStr | Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction |
title_full_unstemmed | Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction |
title_short | Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction |
title_sort | impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373896/ https://www.ncbi.nlm.nih.gov/pubmed/32432414 http://dx.doi.org/10.1002/ehf2.12734 |
work_keys_str_mv | AT watanabeken impactofplasmaxanthineoxidoreductaseactivityinpatientswithheartfailurewithpreservedejectionfraction AT watanabetetsu impactofplasmaxanthineoxidoreductaseactivityinpatientswithheartfailurewithpreservedejectionfraction AT otakiyoichiro impactofplasmaxanthineoxidoreductaseactivityinpatientswithheartfailurewithpreservedejectionfraction AT shishidotetsuro impactofplasmaxanthineoxidoreductaseactivityinpatientswithheartfailurewithpreservedejectionfraction AT murasetakayo impactofplasmaxanthineoxidoreductaseactivityinpatientswithheartfailurewithpreservedejectionfraction AT nakamuratakashi impactofplasmaxanthineoxidoreductaseactivityinpatientswithheartfailurewithpreservedejectionfraction AT katoshigehiko impactofplasmaxanthineoxidoreductaseactivityinpatientswithheartfailurewithpreservedejectionfraction AT tamuraharutoshi impactofplasmaxanthineoxidoreductaseactivityinpatientswithheartfailurewithpreservedejectionfraction AT nishiyamasatoshi impactofplasmaxanthineoxidoreductaseactivityinpatientswithheartfailurewithpreservedejectionfraction AT takahashihiroki impactofplasmaxanthineoxidoreductaseactivityinpatientswithheartfailurewithpreservedejectionfraction AT arimototakanori impactofplasmaxanthineoxidoreductaseactivityinpatientswithheartfailurewithpreservedejectionfraction AT watanabemasafumi impactofplasmaxanthineoxidoreductaseactivityinpatientswithheartfailurewithpreservedejectionfraction |